U.S. House of Representatives Committee on the Judiciary
05/15/2025 | Press release | Distributed by Public on 05/15/2025 10:14
New Information Suggests Senior Pfizer Executives Conspired to Delay COVID-19 Vaccine Clinical Testing to Influence 2020 Election
WASHINGTON, D.C.- House Judiciary Committee Chairman Jim Jordan (R-OH) sent letters to the Chairman and CEO of Pfizer, Dr. Albert Bourla, and Pfizer's former Global Head of Vaccines Research and Development, Dr. Philip Dormitzer, after new information appears to suggest that senior Pfizer executives conspired to withhold data about Pfizer's COVID-19 vaccine to influence the 2020 presidential election.
On March 26, 2025, the Wall Street Journal reported that authorities were in possession of information that originated from a former senior Pfizer executive related to whether Pfizer "sat on the positive results of clinical trials" of its COVID-19 vaccine so as to influence the 2020 presidential election. The Journal identified Dr. Philip Dormitzer as the former Pfizer executive, and reported that he disclosed this information to his then-current employer, GSK plc, in "late 2024" following President Trump's election.
On April 9, 2025, the Committee wrote to GSK requesting additional information about these allegations. GSK responded on April 16, 2025. In its letter to the Committee, GSK stated:
"In November 2024, shortly after the election, Dr. Dormitzer approached a representative from the GSK human resources team to speak about a potential relocation abroad. As the human resources representative recalls, in their meeting, Dr. Dormitzer was visibly upset; he requested that he be relocated to Canada due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine. According to the human resources representative, when asked what prompted his request, Dr. Dormitzer made a comment to the effect of: 'Let's just say it wasn't a coincidence, the timing of the vaccine.'"
GSK further informed the Committee that Dr. Dormitzer had told GSK employees that "in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year."
Although it is unclear which Pfizer R&D employees were involved with Dr. Dormitzer in the decision to delay the clinical testing, Dr. Dormitzer represented to GSK that Pfizer's CEO was not aware of the delay.
Read the full letter to Dr. Albert Bourla here.
Read the full letter to Dr. Philip Dormitzer here.
On March 26, 2025, the Wall Street Journal reported that authorities were in possession of information that originated from a former senior Pfizer executive related to whether Pfizer "sat on the positive results of clinical trials" of its COVID-19 vaccine so as to influence the 2020 presidential election. The Journal identified Dr. Philip Dormitzer as the former Pfizer executive, and reported that he disclosed this information to his then-current employer, GSK plc, in "late 2024" following President Trump's election.
On April 9, 2025, the Committee wrote to GSK requesting additional information about these allegations. GSK responded on April 16, 2025. In its letter to the Committee, GSK stated:
"In November 2024, shortly after the election, Dr. Dormitzer approached a representative from the GSK human resources team to speak about a potential relocation abroad. As the human resources representative recalls, in their meeting, Dr. Dormitzer was visibly upset; he requested that he be relocated to Canada due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine. According to the human resources representative, when asked what prompted his request, Dr. Dormitzer made a comment to the effect of: 'Let's just say it wasn't a coincidence, the timing of the vaccine.'"
GSK further informed the Committee that Dr. Dormitzer had told GSK employees that "in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year."
Although it is unclear which Pfizer R&D employees were involved with Dr. Dormitzer in the decision to delay the clinical testing, Dr. Dormitzer represented to GSK that Pfizer's CEO was not aware of the delay.
Read the full letter to Dr. Albert Bourla here.
Read the full letter to Dr. Philip Dormitzer here.
###
U.S. House of Representatives Committee on the Judiciary published this content on May 15, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 15, 2025 at 16:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io